Tags

Type your tag names separated by a space and hit enter

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Emerg Microbes Infect. 2021 Dec; 10(1):1598-1608.EM

Abstract

Since the outbreak of COVID-19, a variety of vaccine platforms have been developed. Amongst these, inactivated vaccines have been authorized for emergency use or conditional marketing in many countries. To further enhance the protective immune responses in populations that have completed vaccination regimen, we investigated the immunogenic characteristics of different vaccine platforms and tried homologous or heterologous boost strategy post two doses of inactivated vaccines in a mouse model. Our results showed that the humoral and cellular immune responses induced by different vaccines when administered individually differ significantly. In particular, inactivated vaccines showed relatively lower level of neutralizing antibody and T cell responses, but a higher IgG2a/IgG1 ratio compared with other vaccines. Boosting with either recombinant subunit, adenovirus vectored or mRNA vaccine after two-doses of inactivated vaccine further improved both neutralizing antibody and Spike-specific Th1-type T cell responses compared to boosting with a third dose of inactivated vaccine. Our results provide new ideas for prophylactic inoculation strategy of SARS-CoV-2 vaccines.

Authors+Show Affiliations

National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34278956

Citation

Zhang, Jialu, et al. "Boosting With Heterologous Vaccines Effectively Improves Protective Immune Responses of the Inactivated SARS-CoV-2 Vaccine." Emerging Microbes & Infections, vol. 10, no. 1, 2021, pp. 1598-1608.
Zhang J, He Q, An C, et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg Microbes Infect. 2021;10(1):1598-1608.
Zhang, J., He, Q., An, C., Mao, Q., Gao, F., Bian, L., Wu, X., Wang, Q., Liu, P., Song, L., Huo, Y., Liu, S., Yan, X., Yang, J., Cui, B., Li, C., Wang, J., Liang, Z., & Xu, M. (2021). Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerging Microbes & Infections, 10(1), 1598-1608. https://doi.org/10.1080/22221751.2021.1957401
Zhang J, et al. Boosting With Heterologous Vaccines Effectively Improves Protective Immune Responses of the Inactivated SARS-CoV-2 Vaccine. Emerg Microbes Infect. 2021;10(1):1598-1608. PubMed PMID: 34278956.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. AU - Zhang,Jialu, AU - He,Qian, AU - An,Chaoqiang, AU - Mao,Qunying, AU - Gao,Fan, AU - Bian,Lianlian, AU - Wu,Xing, AU - Wang,Qian, AU - Liu,Pei, AU - Song,Lifang, AU - Huo,Yaqian, AU - Liu,Siyuan, AU - Yan,Xujia, AU - Yang,Jinghuan, AU - Cui,Bopei, AU - Li,Changgui, AU - Wang,Junzhi, AU - Liang,Zhenglun, AU - Xu,Miao, PY - 2021/7/20/pubmed PY - 2021/8/31/medline PY - 2021/7/19/entrez KW - Heterologous KW - IgG subtypes KW - SARS-CoV-2 KW - T cell response KW - inactivated KW - neutralizing antibody KW - prime-boost KW - vaccine SP - 1598 EP - 1608 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 10 IS - 1 N2 - Since the outbreak of COVID-19, a variety of vaccine platforms have been developed. Amongst these, inactivated vaccines have been authorized for emergency use or conditional marketing in many countries. To further enhance the protective immune responses in populations that have completed vaccination regimen, we investigated the immunogenic characteristics of different vaccine platforms and tried homologous or heterologous boost strategy post two doses of inactivated vaccines in a mouse model. Our results showed that the humoral and cellular immune responses induced by different vaccines when administered individually differ significantly. In particular, inactivated vaccines showed relatively lower level of neutralizing antibody and T cell responses, but a higher IgG2a/IgG1 ratio compared with other vaccines. Boosting with either recombinant subunit, adenovirus vectored or mRNA vaccine after two-doses of inactivated vaccine further improved both neutralizing antibody and Spike-specific Th1-type T cell responses compared to boosting with a third dose of inactivated vaccine. Our results provide new ideas for prophylactic inoculation strategy of SARS-CoV-2 vaccines. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/34278956/Boosting_with_heterologous_vaccines_effectively_improves_protective_immune_responses_of_the_inactivated_SARS_CoV_2_vaccine_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2021.1957401 DB - PRIME DP - Unbound Medicine ER -